Low-density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin/ezetimibe combination therapy: Real-world evidence
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jeongmin | - |
dc.contributor.author | Lee, Sue Hyun | - |
dc.contributor.author | Kim, Hyunah | - |
dc.contributor.author | Lee, Seung-Hwan | - |
dc.contributor.author | Cho, Jae Hyoung | - |
dc.contributor.author | Lee, Hyunyong | - |
dc.contributor.author | Yim, Hyeon Woo | - |
dc.contributor.author | Yoon, Kun-Ho | - |
dc.contributor.author | Kim, Hun-Sung | - |
dc.contributor.author | Kim, Ju Han | - |
dc.date.accessioned | 2023-06-17T08:42:25Z | - |
dc.date.available | 2023-06-17T08:42:25Z | - |
dc.date.created | 2023-06-17 | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 0269-4727 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/88139 | - |
dc.description.abstract | What is known and objectives This study investigated the additional low-density lipoprotein cholesterol (LDL-C) reductions and target (LDL-C < 100 mg/dL) achievement rates in patients after switching from statin monotherapy to statin/ezetimibe combination therapy, in clinical practice. Methods This retrospective study used data recovered from the electronic medical record systems of two tertiary care medical centres for patients treated between 2015 and 2017. Patients prescribed statin/ezetimibe combination therapy after switching from statin monotherapy were enrolled. The observed LDL-C reductions and the percentage of patients achieving LDL-C levels of <100 mg/dL, after 3 months of treatment, were assessed relative to baseline values. Results and discussion A total of 4252 patients with prescriptions for statin/ezetimibe combination therapy were enrolled. Changing from statin monotherapy to the combination therapy resulted in additional LDL-C level reductions of 31.0-41.0% (all intensity groups,P < .01). Similarly, 88.3-91.1% of the enrolled patients successfully achieved LDL-C levels of <100 mg/dL (all intensity groups,P < .01). A subgroup analysis of patients with baseline LDL-C levels >= 100 mg/dL showed that switching from moderate- or high-intensity statin monotherapy to a rosuvastatin/ezetimibe combination showed greater LDL-C reductions than did switching to an atorvastatin/ezetimibe combination, within the same statin intensity groups. What is new and conclusion The present study provides real-world evidence of the LDL-C reduction benefits associated with statin/ezetimibe combinations in the clinical practice setting. The results also demonstrate that if statin monotherapy does not effectively help patients reach their target LDL-C goals, changing to a statin/ezetimibe combination prescription may show enhanced LDL-C-lowering effects and improve the likelihood of achieving LDL-C targets, in real practice. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | - |
dc.title | Low-density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin/ezetimibe combination therapy: Real-world evidence | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000575633800001 | - |
dc.identifier.doi | 10.1111/jcpt.13271 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, v.46, no.1, pp.134 - 142 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85092194293 | - |
dc.citation.endPage | 142 | - |
dc.citation.startPage | 134 | - |
dc.citation.title | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | - |
dc.citation.volume | 46 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Lee, Sue Hyun | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | cholesterol | - |
dc.subject.keywordAuthor | dyslipidaemia | - |
dc.subject.keywordAuthor | ezetimibe | - |
dc.subject.keywordAuthor | hydroxymethylglutaryl-CoA reductase inhibitors | - |
dc.subject.keywordAuthor | LDL | - |
dc.subject.keywordPlus | CARDIOVASCULAR-DISEASE | - |
dc.subject.keywordPlus | HIGH-RISK | - |
dc.subject.keywordPlus | COMPARATIVE EFFICACY | - |
dc.subject.keywordPlus | ESC/EAS GUIDELINES | - |
dc.subject.keywordPlus | LOWERING TREATMENT | - |
dc.subject.keywordPlus | BLOOD CHOLESTEROL | - |
dc.subject.keywordPlus | PRACTICE PATTERNS | - |
dc.subject.keywordPlus | GOAL ATTAINMENT | - |
dc.subject.keywordPlus | LDL-C | - |
dc.subject.keywordPlus | ROSUVASTATIN | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.